Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway

Zhang, Suxian; Leng, Tianyan; Zhang, Qin; Zhao, Qinghua; Nie, Xiaofeng; Yang, Lihua

doi:10.1016/j.biopha.2018.03.071

Cited by 81 publications

(62 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significantly low expression of lncRNA Cancer Susceptibility 2 (CASC2) was identified in ovarian carcinoma. The initiation factor eIF4A3 acted as a CASC2-binding protein [87].…”

Section: Rna-based Alterations Interacting With Mtormentioning

confidence: 99%

The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer

Sobočan

Bračič

Knez

et al. 2020

Cancers

View full text Add to dashboard Cite

Studies of the mechanistic (mammalian) target of rapamycin inhibitors (mTOR) represent a step towards the targeted treatment of gynecological cancers. It has been shown that women with increased levels of mTOR signaling pathway targets have worse prognosis compared to women with normal mTOR levels. Yet, targeting mTOR alone has led to unsatisfactory outcomes in gynecological cancer. The aim of our review was therefore to provide an overview of the most recent clinical results and basic findings on the interplay of mTOR signaling and cold shock proteins in gynecological malignancies. Due to their oncogenic activity, there are promising data showing that mTOR and Y-box-protein 1 (YB-1) dual targeting improves the inhibition of carcinogenic activity. Although several components differentially expressed in patients with ovarian, endometrial, and cervical cancer of the mTOR were identified, there are only a few investigated downstream actors in gynecological cancer connecting them with YB-1. Our analysis shows that YB-1 is an important player impacting AKT as well as the downstream actors interacting with mTOR such as epidermal growth factor receptor (EGFR), Snail or E-cadherin.

show abstract

“…A significantly low expression of lncRNA Cancer Susceptibility 2 (CASC2) was identified in ovarian carcinoma. The initiation factor eIF4A3 acted as a CASC2-binding protein [87].…”

Section: Rna-based Alterations Interacting With Mtormentioning

confidence: 99%

The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer

Sobočan

Bračič

Knez

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…For example, lncRNA H19 enhances tumor growth and indicates a poor prognosis in colorectal cancer by recruiting and binding with eIF4A3 (Han et al, 2016). Sanguinarine inhibits epithelial ovarian cancer development by modulating the lncRNA CASC2-EIF4A3 pathway and/or repressing NF-κB signaling or PI3K/ AKT/mTOR pathway (Zhang et al, 2018). Additionally, eIF4AIII is identified as phosphoproteins in HCC MHCC97-H cells (high metastasis), affecting cell motility (Tian et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Eukaryotic initiation Factor 4AIII facilitates hepatocellular carcinoma cell proliferation, migration, and epithelial‐mesenchymal transition process via antagonistically binding to WD repeat domain 66 with miRNA‐2113

Zhang

Chen

Bao

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the malignant cancers with high incidence and mortality rates worldwide. RNA‐binding protein eukaryotic initiation Factor 4A‐III (eIF4AIII) is a carcinogene in the biological process of tumors and microRNA (miRNA)‐2113 has rarely been studied in cancers, not to mention in HCC. The regulation mechanism between eIF4AIII and miR‐2113 involved in HCC is yet to be explored. The purpose of this research is to probe the function role and associated underlying mechanism of eIF4AIII participated in HCC. The results revealed that eIF4AIII was overexpressed in HCC. Lost‐of‐function assays found that eIF4AIII knockdown, WD (Trp‐Asp [tryptophan and asparaginic acid]) repeat domain 66 (WDR66) silence or miR‐2113 promotion repressed cell proliferation, migration, and epithelial‐mesenchymal transition (EMT) process in HCC. Furthermore, eIF4AIII could interact with WDR66 and further stabilize WDR66 messenger RNA. In addition, WDR66 was a target gene of miR‐2113. Besides, WDR66 was antagonistically regulated by eIF4AIII and miR‐2113. Rescue assays verified that eIF4AIII promoted HCC cell proliferation, migration, and EMT process via antagonistically binding to WDR66 with miR‐2113. Taken together, these findings indicated an important role and a novel mechanism of eIF4AIII in HCC, providing an optional therapy for HCC patients.

show abstract

“…Protopine; an alkaloid, has been reported for its anticonvulsant activity, 20 microtubule-stabilizing effects, 21 antiinflammatory activity reducing effects, 22 neuroprotective effects, [23][24] anticholinesterase effects, 25 etc. Sanguinarine compounds have been reported for anticancer, [26][27] anti-osteoporosis, [28][29] and norsanguinarine has been reported for antifungal activity. 30 Hydrastine has been reported for the effects on dopamine biosynthesis, 31 PAK4 kinase inhibition 32 etc.…”

Section: Resultsmentioning

confidence: 99%

GC-MS Analysis of Phytoconstituents in Fractions of Corydalis adiantifolia

Ali¹,

Khan²,

Khan³

et al. 2018

TJNPR

View full text Add to dashboard Cite

Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway

Cited by 81 publications

References 30 publications

The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer

The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer

Eukaryotic initiation Factor 4AIII facilitates hepatocellular carcinoma cell proliferation, migration, and epithelial‐mesenchymal transition process via antagonistically binding to WD repeat domain 66 with miRNA‐2113

GC-MS Analysis of Phytoconstituents in Fractions of Corydalis adiantifolia

Contact Info

Product

Resources

About